Literature DB >> 23326166

Alcohol, postprandial plasma glucose, and prognosis of hepatocellular carcinoma.

Hiroshi Abe1, Yuta Aida, Haruya Ishiguro, Kai Yoshizawa, Tamihiro Miyazaki, Munenori Itagaki, Satoshi Sutoh, Yoshio Aizawa.   

Abstract

AIM: To identify factors associated with prognosis of hepatocellular carcinoma (HCC) after initial therapy.
METHODS: A total of 377 HCC patients who were newly treated at Katsushika Medical Center, Japan from January 2000 to December 2009 and followed up for > 2 years, or died during follow-up, were enrolled. The factors related to survival were first analyzed in 377 patients with HCC tumor stage T1-T4 using multivariate Cox proportional hazards regression analysis. A similar analysis was performed in 282 patients with tumor stage T1-T3. Additionally, factors associated with the period between initial and subsequent therapy were examined in 144 patients who did not show local recurrence. Finally, 214 HCC stage T1-T3 patients who died during the observation period were classified into four groups according to their alcohol consumption and postprandial glucose levels, and differences in their causes of death were examined.
RESULTS: On multivariate Cox proportional hazards regression analysis, the following were significantly associated with survival: underlying liver disease stage [non-cirrhosis/Child-Pugh A vs B/C, hazard ratio (HR): 0.603, 95% CI: 0.417-0.874, P = 0.0079], HCC stage (T1/T2 vs T3/T4, HR: 0.447, 95% CI: 0.347-0.576, P < 0.0001), and mean postprandial plasma glucose after initial therapy (< 200 vs ≥ 200 mg/dL, HR: 0.181, 95% CI: 0.067-0.488, P = 0.0008). In T1-T3 patients, uninterrupted alcohol consumption after initial therapy (no vs yes, HR: 0.641, 95% CI: 0.469-0.877, P = 0.0055) was significant in addition to underlying liver disease stage (non-cirrhosis/Child-Pugh A vs B/C, HR: 0649, 95% CI: 0.476-0.885, P = 0.0068), HCC stage (T1 vs T2/T3, HR: 0.788, 95% CI: 0.653-0.945, P = 0.0108), and mean postprandial plasma glucose after initial therapy (< 200 mg/dL vs ≥ 200 mg/dL, HR: 0.502, 95% CI: 0.337-0.747, P = 0.0005). In patients without local recurrence, time from initial to subsequent therapy for newly emerging HCC was significantly longer in the "postprandial glucose within 200 mg/dL group" than the "postprandial glucose > 200 mg/dL group" (log-rank test, P < 0.05), whereas there was no difference in the period between the "non-alcohol group" (patients who did not drink regularly or those who could reduce their daily consumption to < 20 g) and the "continuation group" (drinkers who continued to drink > 20 g daily). Of 214 T1-T3 patients who died during the observation period, death caused by other than HCC progression was significantly more frequent in "group AL" (patients in the continuation and postprandial glucose within 200 mg/dL groups) than "group N" (patients in the non-alcohol and postprandial glucose within 200 mg/dL groups) (P = 0.0016).
CONCLUSION: This study found that abstinence from habitual alcohol consumption and intensive care for diabetes mellitus were related to improved prognosis in HCC patients.

Entities:  

Keywords:  Alcohol consumption; Diabetes mellitus; Hepatocellular carcinoma; Initial therapy; Local recurrence; Postprandial plasma glucose level; Prognosis; Survival

Mesh:

Substances:

Year:  2013        PMID: 23326166      PMCID: PMC3542757          DOI: 10.3748/wjg.v19.i1.78

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  26 in total

1.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

2.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  P Angulo; J C Keach; K P Batts; K D Lindor
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

3.  Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score.

Authors:  Masatoshi Kudo; Hobyung Chung; Seiji Haji; Yukio Osaki; Hiroko Oka; Toshihito Seki; Hiroshi Kasugai; Yo Sasaki; Takashi Matsunaga
Journal:  Hepatology       Date:  2004-12       Impact factor: 17.425

4.  Clinicopathologic study on hepatocellular carcinoma negative for hepatitis B surface antigen and antibody to hepatitis C virus.

Authors:  K Noguchi; O Nakashima; Y Nakashima; K Shiota; H Nawata; M Kojiro
Journal:  Int J Mol Med       Date:  2000-12       Impact factor: 4.101

5.  The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies.

Authors:  Leon A Adams; Schuyler Sanderson; Keith D Lindor; Paul Angulo
Journal:  J Hepatol       Date:  2005-01       Impact factor: 25.083

6.  A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis.

Authors:  K Ikeda; S Saitoh; I Koida; Y Arase; A Tsubota; K Chayama; H Kumada; M Kawanishi
Journal:  Hepatology       Date:  1993-07       Impact factor: 17.425

7.  Report of the 15th follow-up survey of primary liver cancer.

Authors:  Iwao Ikai; Yuji Itai; Kiwamu Okita; Masao Omata; Masamichi Kojiro; Kenichi Kobayashi; Yasuni Nakanuma; Shunji Futagawa; Masatoshi Makuuchi; Yoshio Yamaoka
Journal:  Hepatol Res       Date:  2004-01       Impact factor: 4.288

8.  National survey of hepatocellular carcinoma in heavy drinkers in Japan.

Authors:  Yoshinori Horie; Yoshiyuki Yamagishi; Mikio Kajihara; Shinzo Kato; Hiromasa Ishii
Journal:  Alcohol Clin Exp Res       Date:  2003-08       Impact factor: 3.455

9.  Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with nonviral hepatitis.

Authors:  Yusuke Kawamura; Kenji Ikeda; Yasuji Arase; Hiromi Yatsuji; Hitomi Sezaki; Tetsuya Hosaka; Norio Akuta; Masahiro Kobayashi; Satoshi Saitoh; Fumitaka Suzuki; Yoshiyuki Suzuki; Hiromitsu Kumada
Journal:  J Gastroenterol Hepatol       Date:  2008-08-17       Impact factor: 4.029

10.  Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways.

Authors:  G Svegliati-Baroni; F Ridolfi; A Di Sario; A Casini; L Marucci; G Gaggiotti; P Orlandoni; G Macarri; L Perego; A Benedetti; F Folli
Journal:  Hepatology       Date:  1999-06       Impact factor: 17.425

View more
  4 in total

1.  Obesity is Independently Associated With Increased Risk of Hepatocellular Cancer-related Mortality: A Systematic Review and Meta-Analysis.

Authors:  Arjun Gupta; Avash Das; Kaustav Majumder; Nivedita Arora; Helen G Mayo; Preet P Singh; Muhammad S Beg; Siddharth Singh
Journal:  Am J Clin Oncol       Date:  2018-09       Impact factor: 2.339

Review 2.  Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease?

Authors:  Antonella Scalera; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

3.  Hyperglycemia-Induced miR-467 Drives Tumor Inflammation and Growth in Breast Cancer.

Authors:  Jasmine Gajeton; Irene Krukovets; Santoshi Muppala; Dmitriy Verbovetskiy; Jessica Zhang; Olga Stenina-Adognravi
Journal:  Cancers (Basel)       Date:  2021-03-16       Impact factor: 6.639

4.  Occupational Class and Cancer Survival in Korean Men: Follow-Up Study of Nation-Wide Working Population.

Authors:  Hye-Eun Lee; Masayoshi Zaitsu; Eun-A Kim; Ichiro Kawachi
Journal:  Int J Environ Res Public Health       Date:  2020-01-01       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.